What should you eat on a GLP-1 like Mounjaro or Ozempic?

The short answer

Evidence tier: 2 — based on a 2025 joint advisory from four obesity and nutrition societies, which pools trial data and expert consensus rather than testing specific diets in GLP-1 users.

On a GLP-1 such as tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy), the goal shifts from eating less, which the drug largely handles, to eating well enough within a much smaller appetite. Reviews of dietary studies find people on these drugs eat roughly 16–39% fewer calories, and the 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society names the consequences: nutrient shortfalls, loss of muscle and bone, and gastrointestinal side effects that small food choices can make better or worse.

In practice that means protein first, mostly minimally processed foods, small regular meals that go easy on fat, and treating very low intake as a risk rather than a win. Targets for protein, calories and supplements depend on your weight, kidney function, diabetes medication and history, so discuss them with your prescriber or a registered dietitian.

How much protein do you need on a GLP-1?

Evidence tier: 2 — the ranges come from the joint advisory and an earlier protein review; the lean-mass figures are from the STEP 1 randomised trial, but no trial has tested a protein target specifically in GLP-1 users.

Protein dominates because of body composition. In the STEP 1 trial of semaglutide 2.4 mg, the advisory notes, the average 13.6 kg weight reduction was about 8.3 kg fat (62%) and 5.3 kg lean mass (38%), and it estimates that roughly a fifth of total weight lost was muscle. Modelling cited in the same paper puts muscle at 10–15% of weight lost in women and 20–25% in men in the absence of structured strength training. The advisory reports lean-mass reduction in the SURMOUNT-1 tirzepatide trial as well. Lean-mass loss is expected with any large weight loss; the aim is to limit it, not to prevent it entirely.

What the advisory actually says about intake:

• The general adult recommended daily allowance is 0.8 g per kg of body weight, and that value is under review.
• Higher targets of 1.2–1.6 g/kg have been proposed during active weight reduction, citing earlier work including a review on protein in weight loss and maintenance (Leidy et al., 2015).
• In people with obesity, using actual body weight can overestimate needs, so an absolute target of roughly 80–120 g a day (about 16–24% of energy on a 2,000 kcal diet) is offered as a simpler alternative.
• Intake should not fall below 0.4–0.5 g/kg, and prolonged intake at or above 2 g/kg should be avoided.

With a small appetite, eating the protein part of a meal first raises the chance you get it in, a tactic the advisory suggests. And protein alone does not protect muscle; resistance training is the other half, which our guide to muscle loss on GLP-1s covers in depth. If you have kidney disease, protein targets need to be set with your clinician rather than taken from a range.

What should a plate look like on Mounjaro or Ozempic?

Evidence tier: 2 — the food lists reproduce the joint advisory's dietary table, which draws on general obesity nutrition evidence rather than GLP-1-specific trials.

The advisory's "encourage" list is a familiar healthy-eating pattern; it matters more because every bite now carries more of the day's nutrition:

1. Start with a protein anchor: fish, poultry, eggs, yoghurt or other dairy, tofu, beans or lentils.
2. Add vegetables or fruit, increasing fibre gradually.
3. Choose whole grains such as oats, quinoa or brown rice, in modest portions.
4. Use plant fats like olive oil, nuts and seeds, in amounts that do not trigger nausea.
5. Drink regularly through the day, since less food also means less water from food.
6. Keep meals small and regular; the advisory lists long gaps without eating and large meals among habits to minimise.

To minimise: refined grains and added sugars, sugary drinks, red and processed meats, most fast food, and ultra-processed snacks. "Minimise" is not "never"; the same table encourages portion-controlled treats and flexibility.

At low intakes, the advisory lists iron, calcium, magnesium, zinc and vitamins A, D, E, K, B1, B12 and C as nutrients of concern, and says supplements such as vitamin D, calcium, B12 or a multivitamin can be considered based on individual need. Whether you need any, and at what dose, is for your prescriber to judge, ideally with blood tests.

What foods make side effects worse?

Evidence tier: 3 — clinical-practice recommendations and a mechanistic review on gastric emptying; the food-symptom links are plausible and widely used, but have not been tested in controlled trials.

GLP-1 drugs slow gastric emptying, which helps keep you full and is also why some meals now feel worse. Clinical recommendations for managing GI side effects (Wharton et al., 2022) and a review on meal composition (Gentinetta et al., 2024) point to the same culprits:

• High-fat, fried or greasy meals slow emptying further; avoiding fatty foods is part of standard advice for nausea, and users often link greasy meals to reflux and sulphur burps.
• Large portions stretch a stomach that is already emptying slowly. Stopping at the first sign of fullness matters more than finishing the plate.
• Eating late makes it more likely that a heavy evening meal is still sitting in the stomach at bedtime, which is why the review focuses on lighter evening meals.
• Very high-fibre or very high-fat foods in the first days of treatment or after a dose increase can worsen nausea, according to the advisory, even though fibre is helpful for constipation later on.
• Fizzy drinks and eating quickly are often reported to add to bloating, based on experience rather than trials.

The advisory notes that watery, low-viscosity foods leave the stomach faster while protein and fat slow it, a real trade-off: spreading protein across several smaller meals is often easier than one large protein-and-fat meal.

For symptom-specific strategies, see our nausea guide and constipation guide rather than repeating them here.

What if you can barely eat?

Evidence tier: 2 — risk thresholds and the dehydration-kidney link come from the joint advisory; the red-flag list reflects standard GLP-1 safety warnings and clinical judgement.

On higher doses some people forget to eat or feel full after a few bites. The advisory warns that intakes below about 1,200 kcal a day for women and 1,800 kcal for men make it hard to meet vitamin and mineral needs. These are population thresholds for nutrient risk, not personal targets. It also describes a cycle in which nausea leads to not eating, which worsens nausea, and suggests a small breakfast followed by small meals every three to four hours with adequate fluids.

When appetite is very low, nutrient-dense options that are easy to get down, such as yoghurt, eggs, milk, soups, smoothies, or a protein shake, can bridge the gap. If eating too little is persistent rather than an occasional bad day, raise it with your prescriber; a slower dose escalation or staying on a lower dose is a common clinical response.

Contact a clinician promptly if you have:

• Vomiting or diarrhoea that stops you keeping fluids down, or signs of dehydration such as dizziness on standing, very dark urine or passing very little urine. The advisory notes kidney problems after dehydration from nausea and vomiting.
• Severe or persistent abdominal pain, especially pain spreading to the back, or pain in the upper right abdomen with fever or yellowing of the skin or eyes (see our gallbladder and pancreatitis guide).
• Shakiness, sweating or confusion if you also take insulin or a sulfonylurea, since low blood sugar is more likely when eating drops.
• Fainting, marked weakness, or weight falling much faster than your prescriber expected.
• Eating behaviour that feels out of control, including restricting on purpose or a history of disordered eating, which the advisory says should be screened for before treatment.

How do you eat out or drink on a GLP-1?

Evidence tier: 4 — practical guidance extrapolated from the side-effect evidence above; no studies examine restaurant eating on GLP-1s specifically.

Restaurant portions are large and often fatty, so order a starter-sized main or share, pick grilled or baked protein, ask for sauces on the side, and take leftovers home. If your dose day tends to bring nausea, scheduling social meals away from the first day or two after injection is a reasonable thing to try.

The advisory lists minimal alcohol intake among its recommendations, and many people report that alcohol hits harder or appeals less. Our alcohol and GLP-1s guide covers the details, and the daily-life guide covers travel and routines.

What do users report?

Evidence tier: 5 — keyword counts from anonymised public forum posts; they show what people talk about, not what works.

We counted posts in the site's anonymised Reddit dataset of 3,710 peptide posts from 7 June to 5 November 2026. Of these, 2,623 were tagged to a GLP-1-type drug (tirzepatide, semaglutide, retatrutide or similar), and 1,151 of those (44%) mentioned eating, food, meals, calories, protein, diet, hunger or appetite. Tirzepatide accounted for most of them (835), followed by semaglutide (270) and retatrutide (208); some posts named more than one drug. Across the full dataset, 57 post titles were questions about eating or food.

Within those 1,151 posts, the most common themes, by keyword match, were:

• Protein: 277 posts (24%). Where a gram figure for protein appeared (66 mentions), the median was 120 g, though this mixes daily targets with per-meal or per-shake amounts.
• "Food noise" (the quieting of constant food thoughts): 242 (21%).
• Nausea or vomiting: 198 (17%).
• Sugar and sweets, usually reduced cravings: 132 (11%), and muscle or lean mass: 132 (11%).
• Eating too little or having no appetite: 118 (10%).
• Constipation and fibre: 67 each (6%); hydration: 61 (5%); alcohol: 50 (4%); greasy food: 45 (4%); restaurants: 23 (2%).

The recurring pattern was relief that cravings had faded, mixed with uncertainty about eating enough and hitting a protein number on very little appetite, which matches the gaps the advisory identifies.

Limitations

This is an educational guide, not medical or dietary advice.

• No trial has tested a specific diet or protein target in GLP-1 users; the ranges are expert consensus from general weight-loss research.
• We read the advisory's full text and the other papers' abstracts; body-composition figures for STEP 1 are quoted as reported in the advisory.
• The forum counts are keyword matches from a self-selected, mostly tirzepatide-using group.
• Needs differ with kidney disease, diabetes medication, pregnancy, older age and a history of disordered eating; all of these need individual advice.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

On Mounjaro, Ozempic or any other GLP-1, the drug takes care of eating less. Your job is to make the smaller amount count: protein first and spread through the day, a plate built mostly from minimally processed foods, small regular meals that go easy on fat while your stomach adjusts, and enough fluid. Treat a very low intake as a problem to solve, not a bonus, and know the symptoms that mean you should call someone. Then take the specifics, from your protein target to whether you need a supplement, to your prescriber or a registered dietitian.

Related on this site

• Muscle loss on GLP-1s: how to prevent it
• GLP-1 nausea: why it happens and how to manage it
• GLP-1 constipation
• Living with a GLP-1: the daily-life guide
• Alcohol and GLP-1s
• GLP-1 fatigue and low energy
• Does Ozempic cause hair loss?
• GLP-1 side effects and how to manage them
• Semaglutide vs tirzepatide
• Weight-loss pillar

References

• Mozaffarian D, Agarwal M, Aggarwal M, et al. 2025. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 122(1):344-367. PMID 40450457 · doi:10.1016/j.ajcnut.2025.04.023. Co-published in Obesity (Silver Spring) 33(8):1475-1503, PMID 40445127.
• Christensen S, Robinson K, Thomas S, Williams DR. 2024. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: a narrative review and discussion of research needs. Obes Pillars. 11:100121. PMID 39175746 · doi:10.1016/j.obpill.2024.100121
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 384(11):989-1002. PMID 33567185 · doi:10.1056/NEJMoa2032183
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 · doi:10.1056/NEJMoa2206038
• Leidy HJ, Clifton PM, Astrup A, et al. 2015. The role of protein in weight loss and maintenance. Am J Clin Nutr. 101(6):1320S-1329S. PMID 25926512 · doi:10.3945/ajcn.114.084038
• Wharton S, Davies M, Dicker D, et al. 2022. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 134(1):14-19. PMID 34775881 · doi:10.1080/00325481.2021.2002616
• Gentinetta S, Sottotetti F, Manuelli M, Cena H. 2024. Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonist. Diabetes Metab Syndr Obes. 17:4817-4824. PMID 39722834 · doi:10.2147/DMSO.S494919